AR062209A1 - Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. - Google Patents
Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos.Info
- Publication number
- AR062209A1 AR062209A1 ARP070103438A ARP070103438A AR062209A1 AR 062209 A1 AR062209 A1 AR 062209A1 AR P070103438 A ARP070103438 A AR P070103438A AR P070103438 A ARP070103438 A AR P070103438A AR 062209 A1 AR062209 A1 AR 062209A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- trifluoromethyl
- radical
- represent
- pirazolopirimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
Abstract
Reivindicacion 1: Un compuesto de pirazolo-pirimidina de formula (1) donde R1 representa cloro o bromo; R2 y R3 cada uno independientemente representa hidrogeno, alquilo C1-6, cicloalquilo C3-7 o trifluorometilo; o R2 y R3, ambos junto con el átomo de carbono del anillo, representan un grupo carbonilo; R4 y R5 cada uno independientemente representa hidrogeno, alquilo C1-6, cicloalquilo C3-7 o trifluorometilo; o R4 y R5, ambos junto con el átomo de carbono del anillo, representan un grupo carbonilo; R6 y R7 independientemente representan hidrogeno, alquilo C1-6, cicloalquilo C3-7 o trifluorometilo; o R6 y R7, ambos junto con el átomo de carbono del anillo, representan un grupo carbonilo; R2 o R3, junto con R6 y R7, también pueden formar un radical bivalente del grupo CH2-CH2 o CH2-O; R8 representa un radical R9 o un radical R10, donde uno de los dos radicales R8 denota R9 y el otro radical R8 denota R10; R9 representa un grupo cíclico seleccionado de arilo, heteroarilo o heterociclilo, donde el sistema anular puede estar opcionalmente sustituido por uno o dos sustituyentes, que pueden ser iguales o diferentes y que están seleccionados independientemente de halogeno, amino, hidroxilo, nitro, ciano, trifluorometilo, trifluorometoxi, alquiloC1-6, hidroxialquilo C1-6 y/o alcoxi C1-6; R10 representa hidrogeno o alquilo C1-6; y los isomeros opticos, sales, hidratos, solvatos y polimorfos farmacéuticamente aceptables de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83582006P | 2006-08-04 | 2006-08-04 | |
| US87754406P | 2006-12-28 | 2006-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062209A1 true AR062209A1 (es) | 2008-10-22 |
Family
ID=38710494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103437A AR063680A1 (es) | 2006-08-04 | 2007-08-03 | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. |
| ARP070103438A AR062209A1 (es) | 2006-08-04 | 2007-08-03 | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. |
| ARP070103439A AR062210A1 (es) | 2006-08-04 | 2007-08-03 | Pirazolopirimidinas sustituidas, un proceso para su preparacion y su uso como medicamento |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103437A AR063680A1 (es) | 2006-08-04 | 2007-08-03 | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103439A AR062210A1 (es) | 2006-08-04 | 2007-08-03 | Pirazolopirimidinas sustituidas, un proceso para su preparacion y su uso como medicamento |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20080032998A1 (es) |
| EP (3) | EP2295439A1 (es) |
| JP (2) | JP2010500288A (es) |
| KR (1) | KR20090047450A (es) |
| AR (3) | AR063680A1 (es) |
| AT (2) | ATE494289T1 (es) |
| AU (2) | AU2007280429A1 (es) |
| BR (2) | BRPI0714622A2 (es) |
| CA (2) | CA2659876A1 (es) |
| CY (1) | CY1112003T1 (es) |
| DE (2) | DE602007011773D1 (es) |
| DK (1) | DK2054416T3 (es) |
| HR (1) | HRP20110128T1 (es) |
| IL (2) | IL196007A0 (es) |
| MX (2) | MX2009000919A (es) |
| PL (1) | PL2054416T3 (es) |
| PT (1) | PT2054416E (es) |
| RU (2) | RU2450004C2 (es) |
| TW (3) | TW200823215A (es) |
| WO (3) | WO2008015269A1 (es) |
| ZA (1) | ZA200810605B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008056176A1 (en) * | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
| HK1136565A1 (en) * | 2007-03-31 | 2010-07-02 | Intervet Int Bv | Processes for making zilpaterol and salts thereof |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| US8703809B2 (en) * | 2008-06-30 | 2014-04-22 | Novartis Ag | Combination products |
| US20120283274A1 (en) | 2009-11-25 | 2012-11-08 | Patrick Plitt | Crystalline forms of substituted pyrazolopyrimidines |
| US8703946B2 (en) | 2010-12-08 | 2014-04-22 | Vanderbilt University | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors |
| US8865725B2 (en) | 2011-03-15 | 2014-10-21 | Vanderbilt University | Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors |
| JP2014508172A (ja) * | 2011-03-15 | 2014-04-03 | ヴァンダービルト ユニバーシティー | Ｍｇｌｕｒ５受容体のアロステリック調節剤としての置換イミダゾピリミジン−５（６ｈ）−オン |
| WO2012139876A1 (en) | 2011-04-14 | 2012-10-18 | Merz Pharma Gmbh & Co. Kgaa | Enteric formulations of metabotropic glutamate receptor modulators |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2013087808A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin |
| WO2013087815A1 (en) | 2011-12-15 | 2013-06-20 | Merz Pharma Gmbh & Co. Kgaa | Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof |
| US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| JP5898815B2 (ja) * | 2012-03-29 | 2016-04-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なピラゾロピリミジン |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| JP2015529206A (ja) | 2012-08-25 | 2015-10-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｇａｐｄｈカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置 |
| MA38333A1 (fr) | 2013-02-19 | 2017-02-28 | Pfizer | Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections |
| US9663536B2 (en) | 2013-03-13 | 2017-05-30 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP2016512511A (ja) | 2013-03-13 | 2016-04-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヒト免疫不全ウイルス複製の阻害剤 |
| US9540393B2 (en) | 2013-03-14 | 2017-01-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3036219A4 (en) * | 2013-06-04 | 2017-08-23 | Temple University Of The Commonwealth System Of Higher Education | Novel beta lactams as modulators of glutamate uptake and methods for use thereof |
| US10398142B2 (en) | 2013-11-05 | 2019-09-03 | Temple University Of The Commonwealth System Of Higher Education | Polycationic amphiphiles as antimicrobial agents |
| MX2016005994A (es) | 2013-11-05 | 2017-01-11 | Univ Temple | Anifífilos policatónicos como agentes antimicrobianos. |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| PT3177624T (pt) | 2014-08-06 | 2019-07-11 | Pfizer | Compostos de imidazopiridazina |
| WO2017129801A1 (en) | 2016-01-27 | 2017-08-03 | Universität Zürich | Use of gabaa receptor modulators for treatment of itch |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7305644A (es) | 1972-04-20 | 1973-10-23 | ||
| GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| US3988339A (en) | 1974-02-08 | 1976-10-26 | Smithkline Corporation | Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase |
| US3974283A (en) * | 1974-03-18 | 1976-08-10 | Sandoz, Inc. | N-substituted-4-T-butyl-1-pyridinethiocarboxamides and their use for treatment of inflammation or pain |
| NZ190915A (en) * | 1978-07-31 | 1984-07-31 | Hoffmann La Roche | Oxadiazolotriazine derivatives and pharmaceutical compositions |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| SU768177A1 (ru) * | 1979-04-23 | 1985-08-07 | МГУ им.М.В.Ломоносова | Способ получени ( @ )-(-) или ( @ )-(+)-1=метил-1,2,3,4-тетрагидроизохинолина |
| ZA803591B (en) * | 1979-07-09 | 1981-06-24 | American Cyanamid Co | Substituted pyrazolo(1,5-a)pyrimidines |
| US4340597A (en) * | 1981-04-13 | 1982-07-20 | Schering Corporation | 1-Substituted-4-aryl-1,2,5,6-tetrahydro and hexahydropyridines |
| DE3308554A1 (de) * | 1983-03-10 | 1984-09-13 | Hoechst Ag, 6230 Frankfurt | 1-/1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung |
| WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| US6177443B1 (en) | 1997-03-07 | 2001-01-23 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use |
| PT1009732E (pt) | 1997-06-30 | 2003-10-31 | Merz & Co Gmbh & Co | 1-amino-alquilciclo-hexanos antagonistas do receptor nmda |
| US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| DE19732589A1 (de) * | 1997-07-29 | 1999-02-04 | Huels Chemische Werke Ag | Verfahren zur Herstellung von 1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridin |
| FR2769313B1 (fr) | 1997-10-06 | 2000-04-21 | Sanofi Sa | Derives d'esters hydroxyacetiques, leur procede de preparation et leur utilisation comme intermediaires de synthese |
| EP1037878A2 (en) | 1997-11-21 | 2000-09-27 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| KR100588249B1 (ko) | 1997-12-25 | 2006-06-13 | 메이지 세이카 가부시키가이샤 | 테트라하이드로벤즈인돌 유도체 |
| MXPA01002173A (es) | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
| US20020049223A1 (en) | 1999-11-05 | 2002-04-25 | Elmore Steven W. | Quinoline and naphthyridine carboxylic acid antibacterials |
| AU776933B2 (en) * | 1999-12-28 | 2004-09-23 | Eisai R&D Management Co., Ltd. | Heterocyclic compounds having sulfonamide groups |
| GB0110338D0 (en) | 2001-04-27 | 2001-06-20 | Sb Pharmco Inc | Novel processes |
| GB0118752D0 (en) * | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
| ATE541847T1 (de) * | 2001-11-01 | 2012-02-15 | Icagen Inc | Pyrazolopyrimidine als natriumkanalblocker |
| KR20040097375A (ko) | 2002-04-23 | 2004-11-17 | 시오노기 앤드 컴파니, 리미티드 | 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제 |
| WO2003101993A1 (en) | 2002-06-04 | 2003-12-11 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| AU2003264018A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
| EP1615697A2 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| EP1773880A4 (en) | 2004-06-08 | 2009-09-09 | Novartis Vaccines & Diagnostic | ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE |
| KR20070045254A (ko) | 2004-08-02 | 2007-05-02 | 슈바르츠 파르마 악티엔게젤샤프트 | 인돌리진 카르복사미드 및 그 아자 및 디아자유도체 |
| WO2006077401A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Pyrrolopyridines useful in the treatment of inflammation |
-
2007
- 2007-08-03 AR ARP070103437A patent/AR063680A1/es not_active Application Discontinuation
- 2007-08-03 TW TW096128665A patent/TW200823215A/zh unknown
- 2007-08-03 CA CA002659876A patent/CA2659876A1/en not_active Abandoned
- 2007-08-03 BR BRPI0714622-1A patent/BRPI0714622A2/pt not_active IP Right Cessation
- 2007-08-03 BR BRPI0714766-0A patent/BRPI0714766A2/pt not_active IP Right Cessation
- 2007-08-03 MX MX2009000919A patent/MX2009000919A/es active IP Right Grant
- 2007-08-03 DE DE602007011773T patent/DE602007011773D1/de active Active
- 2007-08-03 RU RU2009107686/04A patent/RU2450004C2/ru not_active IP Right Cessation
- 2007-08-03 TW TW096128671A patent/TWI399376B/zh not_active IP Right Cessation
- 2007-08-03 PT PT07788196T patent/PT2054416E/pt unknown
- 2007-08-03 EP EP10190596A patent/EP2295439A1/en not_active Withdrawn
- 2007-08-03 PL PL07788196T patent/PL2054416T3/pl unknown
- 2007-08-03 CA CA002659871A patent/CA2659871A1/en not_active Abandoned
- 2007-08-03 EP EP07788196.9A patent/EP2054416B8/en active Active
- 2007-08-03 MX MX2009001036A patent/MX2009001036A/es active IP Right Grant
- 2007-08-03 DK DK07788196.9T patent/DK2054416T3/da active
- 2007-08-03 DE DE602007010640T patent/DE602007010640D1/de active Active
- 2007-08-03 JP JP2009522284A patent/JP2010500288A/ja active Pending
- 2007-08-03 AT AT07788196T patent/ATE494289T1/de active
- 2007-08-03 AR ARP070103438A patent/AR062209A1/es unknown
- 2007-08-03 RU RU2009107688/04A patent/RU2009107688A/ru not_active Application Discontinuation
- 2007-08-03 US US11/890,230 patent/US20080032998A1/en not_active Abandoned
- 2007-08-03 US US11/890,199 patent/US7985753B2/en not_active Expired - Fee Related
- 2007-08-03 WO PCT/EP2007/058060 patent/WO2008015269A1/en active Application Filing
- 2007-08-03 TW TW096128661A patent/TW200815432A/zh unknown
- 2007-08-03 US US11/890,211 patent/US7947689B2/en not_active Expired - Fee Related
- 2007-08-03 AT AT07788197T patent/ATE488520T1/de active
- 2007-08-03 JP JP2009522285A patent/JP2009545569A/ja not_active Abandoned
- 2007-08-03 EP EP07788197A patent/EP2054421B1/en active Active
- 2007-08-03 WO PCT/EP2007/058062 patent/WO2008015271A1/en active Application Filing
- 2007-08-03 AU AU2007280429A patent/AU2007280429A1/en not_active Abandoned
- 2007-08-03 AR ARP070103439A patent/AR062210A1/es not_active Application Discontinuation
- 2007-08-03 WO PCT/EP2007/058061 patent/WO2008015270A1/en active Application Filing
- 2007-08-03 AU AU2007280428A patent/AU2007280428B2/en not_active Ceased
- 2007-08-03 KR KR1020097002224A patent/KR20090047450A/ko not_active Application Discontinuation
-
2008
- 2008-12-15 ZA ZA2008/10605A patent/ZA200810605B/en unknown
- 2008-12-17 IL IL196007A patent/IL196007A0/en unknown
- 2008-12-17 IL IL196008A patent/IL196008A0/en unknown
-
2011
- 2011-02-23 HR HR20110128T patent/HRP20110128T1/hr unknown
- 2011-03-21 CY CY20111100303T patent/CY1112003T1/el unknown
- 2011-05-03 US US13/068,150 patent/US20110212956A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
| AR049951A1 (es) | Derivados de ftalazina como inhibidores de parp | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
| AR029717A1 (es) | Derivados del pro-farmaco de 4-fenil-piridina | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| CO5580803A2 (es) | Derivados de piperidin-bencensulfonamida | |
| AR068764A1 (es) | N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah. | |
| CO4900053A1 (es) | Derivados de sulfonamida y -n-(4-aril-tiazol-2-il) y su uso | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| AR061615A1 (es) | Moduladores de receptores metabotropicos de glutamato | |
| AR066604A1 (es) | Derivados de arilamida pirimidona, medicamentos que los contienen y usos terapeuticos para prevenir y/o tratar enfermedades neurodegenerativas fundamentalmente. | |
| AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR066421A1 (es) | Compuestos derivados de piridona | |
| AR053342A1 (es) | Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas | |
| AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
| AR103397A1 (es) | Oxoborazoles microbicidas | |
| AR066603A1 (es) | Derivados de arilamida pirimidona | |
| AR029400A1 (es) | Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |